Having established the regulatory relationship between ER-alpha and RPS24 AS, we next aimed to understand how this splicing event responds to therapeutic interventions and contributes to treatment resistance, which are critical aspects of breast cancer management. This evidence concerns the gene RPS24 and breast cancer.